Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 12, 2025

Broadcom & Lululemon earnings, what AI means for Fed's inflation goals

View original at finance.yahoo.com
Broadcom & Lululemon earnings, what AI means for Fed's inflation goals Morning Brief host Julie Hyman takes a look at several of the day's developing stories on December 12, 2025…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Lululemon got away from their core by following and chasing trends

    80% confidence
  • AI market is blowing up by 2030

    80% confidence
  • AI product order backlog of $73 billion is a minimum figure to be shipped over next 6 quarters

    80% confidence
  • Alo came out of nowhere and now has extraordinary influence on young Gen Z and Gen Alpha

    80% confidence
  • RH Q3 results highlight the disruptive nature of the brand despite the worst housing backdrop in decades

    80% confidence
  • What's happening in AI stocks and technology is finally doing exactly what every revolutionary cycle is supposed to do

    80% confidence
  • Calvin McDonald's seven-year tenure is one of the longest for a Lululemon CEO since Chip Wilson

    80% confidence
  • Expected CEO change at Lululemon but sooner than anticipated; momentum slowed post-Thanksgiving with lower margins and higher markdowns

    80% confidence
  • US has a declining population but there's demand for 3% GDP growth annually

    80% confidence
  • There's a need for Federal Reserve policy to be married with a restructuring of the labor market

    80% confidence
  • Customer cooling in AI demand is an overblown hypothesis which frankly won't happen

    80% confidence
  • GPUs from Nvidia and AMD are evolving so fast that it's difficult for custom XPUs, TPUs, ASICs to keep up

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Broadcom & Lululemon earnings, what AI means for Fed's inflation goals — Source | Via News | ViaNews EU